SCHEMBL7564041

SCHEMBL7564041

COC(=O)c1ncccc1CCc1ccc(F)cc1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 2/20 0.51
RORC P51449 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
PARP1 P09874 1/20 0.46
KMT2A Q03164 3/20 0.45
KDM4E B2RXH2 1/20 0.45
HSP90B1 P14625 1/20 0.43
MPO P05164 1/20 0.43
MAPT P10636 1/20 0.42
HDAC6 Q9UBN7 1/20 0.41
NR3C2 P08235 1/20 0.41
PLA2G2A P14555 1/20 0.41
CCR6 P51684 1/20 0.40
HKDC1 Q2TB90 1/20 0.40
CXCR2 P25025 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7961251 0.81 ANO1 (0.46) HSP90AA1L3MBTL1KMT2AKDM4EMAPT
SCHEMBL27729389 0.79 L3MBTL1 (0.53) HSP90AA1RORCL3MBTL1PARP1KMT2A
SCHEMBL7563082 0.78 CCR6 (0.43) HSP90AA1L3MBTL1KMT2AKDM4EHSP90B1
SCHEMBL12948310 0.78 L3MBTL1 (0.55) RORCL3MBTL1PARP1KMT2AKDM4E
SCHEMBL22853851 0.78 L3MBTL1 (0.49) L3MBTL1PARP1KMT2AKDM4EMPO
SCHEMBL535668 0.78 L3MBTL1 (0.58) L3MBTL1PARP1KMT2AKDM4EMPO
SCHEMBL28117989 0.76 PARP1 (0.47) HSP90AA1RORCL3MBTL1PARP1KDM4E
SCHEMBL28677368 0.76 L3MBTL1 (0.57) L3MBTL1PARP1KMT2AKDM4EMPO
SCHEMBL23177721 0.76 L3MBTL1 (0.50) RORCL3MBTL1PARP1KMT2AKDM4E
SCHEMBL29429222 0.76 L3MBTL1 (0.50) RORCL3MBTL1PARP1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020058665-A1 Imidazole derivatives and their use as farnesyl protein transferase inhibitors ASTRAZENECA UK LIMITED 2002-05-16 US disclosed
US-20020052376-A1 Imidazole derivatives and their use as farnesyl protein transferase inhibitors ASTRAZENECA UK LIMITED 2002-05-02 US disclosed
US-6342765-B1 COMPOUNDS THAT INHIBIT FARNESYLATION OF MUTANT RAS GENE PRODUCTS; TREATING DISEASES, ESPECIALLY CANCER, WHICH ARE MEDIATED THROUGH FARNESYLATION OF RAS ASTRAZENECA UK LIMITED (GB) 2002-01-29 US disclosed
EP-1025088-B1 IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS ASTRAZENECA AB (SE) 2001-09-05 EP disclosed
EP-1025088-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS AstraZeneca UK Limited (GB) 2000-08-09 EP disclosed
WO-1999020611-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS ZENECA LIMITED (GB) 1999-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058665-A1 Imidazole derivatives and their use as farnesyl protein transferase inhibitors FNTA, FNTB, RABGGTA HSP90AA1 1017/4885RORC 164/4885L3MBTL1 1562/4885
US-20020052376-A1 Imidazole derivatives and their use as farnesyl protein transferase inhibitors FNTA, FNTB, RABGGTA HSP90AA1 1219/4885RORC 166/4885L3MBTL1 1573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.